Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication NEURONTIN ® is indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy NEURONTIN is indicated for: • Postherpetic neuralgia in adults ( 1 ) • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary…
Gabapentin · 1 trial · 1 indication
Area under the cold pain test Visual Analog Scale (VAS) time curve (AUCcpt 0 to 120 seconds \[sec\]) averaged over the 120 sec for each time point assessed. Participant adjusted 100 millimeter (mm) electronic VAS with range of "no pain" (0) to "maximum pain" (100) at the anchor endpoints of the scale and "moderate pain" at the midpoint. Pain reported while non-dominant hand was placed in thermostatically controlled water bath at 2±1°C for a maximum of 120 sec.
Interpolated average pain (0 to 8 hours): area under the curve (AUC) of average pain (0 to 120 seconds) recorded at each of the time points taken over 8 hour time period divided by 8.
| Arm | Type | Description |
|---|---|---|
| Gabapentin 1200mg | ACTIVE_COMPARATOR | - |
| Diphenhydramine 50 mg | ACTIVE_COMPARATOR | - |
| Morphine 10 mg | ACTIVE_COMPARATOR | - |
| Placebo formulations | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Gabapentin | DRUG | Capsule, single 1200mg dose |
| Diphenhydramine | DRUG | Tablet, single 50mg dose |
| Morphine | DRUG | IV, single 10mg dose |
| Placebo | DRUG | Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion). |
Inclusion Criteria: * Healthy male volunteers having given consent to participate in the study who have no clinically significant anomalies and whose vital signs are within normal range. * Subject having performed the cold pain test reproducibly ie, if the area under the pain-time curve (AUC) must ...
Gabapentin is a small molecule drug developed by Pfizer, Inc. (ticker PFE). It is being studied in Phase 1 clinical development, and its current development indications are undisclosed. Gabapentin is a modulator that acts on multiple calcium channel targets, including CACNA1H, CACNA2D1, CACNA1C, CACNA2D3, CACNA1S, and CACNA2D2.
Gabapentin targets the calcium channel proteins CACNA1H, CACNA2D1, CACNA1C, CACNA2D3, CACNA1S, and CACNA2D2. It is classified as a modulator of these targets. This target profile places gabapentin among small molecule drugs that act on voltage-gated calcium channel subunits.
Gabapentin is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the clinical development of gabapentin as described in its Phase 1 program.
Gabapentin is in Phase 1 clinical development. It is an investigational small molecule and is not described as FDA approved. The Phase 1 program includes one completed trial, and no active trials are currently listed for gabapentin.
Gabapentin has been studied in the Phase 1 trial NCT01119222, titled Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers. The trial was completed in Belgium with 19 enrolled healthy male volunteers aged 18 years and older. It was randomized, double-blind, and placebo-controlled.
Yes, gabapentin is a small molecule drug. It is a modulator of calcium channel targets including CACNA1H, CACNA2D1, CACNA1C, CACNA2D3, CACNA1S, and CACNA2D2, and it is being developed by Pfizer, Inc. (ticker PFE) in Phase 1 clinical development.